Welcome to Leadership: Colby Holtshouse Takes the Helm
May Health is excited to announce the appointment of Colby Holtshouse as the new President and CEO. This transition occurs as the company intensifies its efforts on clinical evaluations surrounding its groundbreaking Ovarian Rebalancing™ technology. Designed to restore ovulation in women suffering from Polycystic Ovary Syndrome (PCOS), a major contributor to infertility, this innovative one-time transvaginal ablation procedure represents a significant advancement in women's health.
Embracing Experience
Colby Holtshouse joins May Health with extensive background and robust leadership expertise, particularly in women's health. Her prior roles at Organon, Alydia Health, and Pelvalon highlight her proven track record in bringing pivotal technologies to market. This depth of experience is particularly relevant as May Health continues to drive its clinical initiatives forward.
A Vision for the Future
Dr. Robert Auerbach, Chairman of May Health, expressed his enthusiasm for Holtshouse's leadership, stating, "We're eager to complete the REBALANCE study, a vital clinical trial meant to support marketing authorization for our Ovarian Rebalancing procedure. Colby's deep expertise will be crucial as we work toward this goal, ensuring the technology is validated and ready for commercialization across various markets."
A Game-Changer for Women’s Health
Holtshouse’s incoming direction comes at a critical juncture for May Health. "May Health stands at the forefront of addressing PCOS, which affects roughly 10% of women and poses serious challenges including infertility," declared Antoine Papiernik, former Chairman of May Health and current Chairman at Sofinnova Partners. Papiernik's enthusiasm reflects the optimistic outlook surrounding Holtshouse's impact on the company's future trajectory.
Innovative Technology: Ovarian Rebalancing
The Ovarian Rebalancing technology is undergoing extensive investigation as a treatment for PCOS-related infertility. Utilizing ultrasound-guided transvaginal procedures to apply radio frequency (RF) energy, the treatment aims to ablate excess androgen-producing tissue in the ovaries. This innovative approach not only aims to restore regular menstrual cycles but also allows for same-day recovery, ensuring minimal discomfort and downtime for patients.
The Path Ahead
With clinical feasibility studies already completed both in Europe and the U.S., May Health is poised to advance its IDE clinical study in the United States. Colby Holtshouse remarked, "Joining May Health at such a critical point is exhilarating. The promising results from earlier feasibility studies boost our hope for the REBALANCE study to provide essential evidence for FDA marketing authorization, leading to broader acceptance of our treatment options for those experiencing PCOS-related infertility. I eagerly anticipate collaborating with the May Health team to bring our Ovarian Rebalancing procedure to women in need."
Understanding PCOS
Polycystic Ovary Syndrome (PCOS) is a prevalent endocrine disorder characterized by imbalanced hormone levels, leading to abnormal ovulation and infertility challenges. Symptoms can include irregular menstrual cycles, excessive hair growth, acne, and a heightened risk for more serious health conditions such as Type 2 diabetes and heart disease. Given its significant impact on women's health, the advances made by May Health in developing treatments for PCOS are crucial.
About May Health
Headquartered in Paris, May Health is actively making strides to address the unique challenges faced by women with PCOS. The medical device company aims to deliver innovative treatments that can offer new hope to those affected by this common yet challenging condition.
Frequently Asked Questions
1. Who is Colby Holtshouse?
Colby Holtshouse is the newly appointed President and CEO of May Health, bringing extensive experience in leadership and women's health.
2. What is the Ovarian Rebalancing technology?
This technology aims to treat infertility in women with PCOS through a one-time transvaginal ablation procedure that restores ovulation.
3. Why is PCOS significant to women's health?
PCOS affects about 10% of women and can lead to serious health issues, including infertility, making effective treatments essential.
4. What is the REBALANCE study?
The REBALANCE study is a vital clinical trial that supports the FDA approval process for the Ovarian Rebalancing treatment.
5. How does May Health’s technology differentiate itself?
May Health’s approach focuses on using an innovative, minimally invasive procedure designed to yield rapid recovery and effectiveness for women suffering from PCOS-related infertility.
